Abstract

BackgroundDiethylcarbamazine (DEC) has been used for many years in the treatment of human lymphatic filariasis. Its mode of action is not well understood, but it is known to interact with the arachidonic acid pathway. Here we have investigated the contribution of the nitric oxide and cyclooxygenase (COX) pathways to the activity of DEC against B. malayi microfilariae in mice.MethodsB. malayi microfilariae were injected intravenously into mice and parasitaemia was measured 24 hours later. DEC was then administered to BALB/c mice with and without pre-treatment with indomethacin or dexamethasone and the parasitaemia monitored. To investigate a role for inducible nitric oxide in DEC's activity, DEC and ivermectin were administered to microfilaraemic iNOS-/- mice and their background strain (129/SV). Western blot analysis was used to determine any effect of DEC on the production of COX and inducible nitric-oxide synthase (iNOS) proteins.ResultsDEC administered alone to BALB/c mice resulted in a rapid and profound reduction in circulating microfilariae within five minutes of treatment. Microfilarial levels began to recover after 24 hours and returned to near pre-treatment levels two weeks later, suggesting that the sequestration of microfilariae occurs independently of parasite killing. Pre-treatment of animals with dexamethasone or indomethacin reduced DEC's efficacy by almost 90% or 56%, respectively, supporting a role for the arachidonic acid and cyclooxygenase pathways in vivo. Furthermore, experiments showed that treatment with DEC results in a reduction in the amount of COX-1 protein in peritoneal exudate cells. Additionally, in iNOS-/- mice infected with B. malayi microfilariae, DEC showed no activity, whereas the efficacy of another antifilarial drug, ivermectin, was unaffected.ConclusionThese results confirm the important role of the arachidonic acid metabolic pathway in DEC's mechanism of action in vivo and show that in addition to its effects on the 5-lipoxygenase pathway, it targets the cyclooxygenase pathway and COX-1. Moreover, we show for the first time that inducible nitric oxide is essential for the rapid sequestration of microfilariae by DEC.

Highlights

  • Diethylcarbamazine (DEC) has been used for many years in the treatment of human lymphatic filariasis

  • Diethylcarbamazine citrate (DEC) has been used in the treatment and control of lymphatic filariasis since 1947 and it continues to play an important role, being one of the drugs used in the Global Programme for the Elimination of Lymphatic Filariasis [1]

  • Action of DEC against microfilariae in vivo in mice In BALB/c mice treated with DEC alone, microfilaraemia levels were reduced by five minutes with a sustained reduction for at least 60 minutes post-treatment (Fig. 1)

Read more

Summary

Introduction

Diethylcarbamazine (DEC) has been used for many years in the treatment of human lymphatic filariasis. Diethylcarbamazine citrate (DEC) has been used in the treatment and control of lymphatic filariasis (caused by the nematodes Wuchereria bancrofti, Brugia malayi and B. timori) since 1947 and it continues to play an important role, being one of the drugs used in the Global Programme for the Elimination of Lymphatic Filariasis [1]. Despite this long period of use, DEC's mode of action is still poorly understood. A role for some of these activities has yet to be demonstrated in vivo and so we have used a mouse model to identify the host factors responsible for the rapid efficacy of DEC

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call